Noticias MoonLake Immunotherapeutics - MLTX | Acciones NASDAQ

Herramientas de nivel profesional para inversores individuales.

Premium

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN...

Form 8-K - Current report

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets...

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase...

Form 4 - Statement of changes in beneficial ownership of securities

Monksdream 4 meses hace

MLTX in an up trend

👍️0

AKATITUS 1 año hace

Sleeping
Come on 70.00

👍️0

Monksdream 1 año hace

MLTX new 52 week high

👍️0

AKATITUS 2 años hace

Haha. Now that's funny. 18,000 share buy at 52.00 dollars.

👍️0

AKATITUS 2 años hace

Damm some big buys at 54.00 WoW

Looks like a good churning. Will tomorrow be the same. ??????

👍️0

MiamiGent 2 años hace

MLTX Started the day with a bang. Falling back, presently

MOONLAKE IMMUNOTHERAPEUTICS
$41.80 +15.92 (+61.51%)
As of Jun-26-202310:46:16 AM ET

https://stockcharts.com/h-sc/ui?s=MLTX

Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
BENZINGA
31 mins ago
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today's session.

MoonLake Immunotherapeutics (NASDAQ:MLTX) jumped 75% to $45.50 after the company's Phase 2 study for Nanobody sonelokimabint met its primary endpoint in hidradenitis suppurativa.

(con't)

👍️0

AKATITUS 2 años hace

So pissed I was trying to sell somethings to buy 40ts them boom 100 bucks F##########

crudeoil24 3 años hace

MoonLake Immunotherapeutics (NASDAQ: MLTX) 10% owner Bihua Chen acquired a total of 5,635,000 shares at an average price of $10.00. To acquire these shares, it cost around $28.5 million.

👍️0

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

MoonLake Immunotherapeutics (MLTX)

Herramientas de nivel profesional para inversores individuales.

MLTX Noticias

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Form 8-K - Current report

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Form 4 - Statement of changes in beneficial ownership of securities

MLTX Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

MoonLake Immunotherapeutics (MLTX) Noticias

MoonLake Immunotherapeutics (MLTX)

Herramientas de nivel profesional para inversores individuales.

MLTX Noticias

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Form 8-K - Current report

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Form 4 - Statement of changes in beneficial ownership of securities

MLTX Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación